NorthRock Partners’s BIOATLA INC BCAB Stock Holding History

NorthRock Partners’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-416	Closed	-$14.3K	–	653
2025 Q3	$14.3K	Buy	+416	New	+$9.6K	﹤0.01%	869

Other funds holding BCAB

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

NorthRock Partners's BCAB Position: Q4 2025 in Review

NorthRock Partners sold out of BIOATLA INC (BCAB) in Q4 2025, closing a stake of 416 shares — an estimated $14.3K sold.

NorthRock Partners first reported a position in BCAB in Q3 2025 and held it in 1 quarter. The position peaked at $14.3K in Q3 2025. 41 funds tracked by Wall St. Rank hold BCAB as of Q4 2025.

NorthRock Partners reported no remaining BIOATLA INC position as of Q4 2025 after selling out during the quarter.
NorthRock Partners sold 416 BIOATLA INC shares in Q4 2025, an estimated $14.3K.
NorthRock Partners first reported a position in BIOATLA INC in Q3 2025 and held it in 1 quarter.
NorthRock Partners's BIOATLA INC position peaked at $14.3K in Q3 2025.
41 funds tracked by Wall St. Rank held BIOATLA INC as of Q4 2025.

Based on NorthRock Partners's 13F filing for Q4 2025, filed 17 Feb 2026.